Patient demographics, baseline and study characteristics

Study [ref.], yearStudy characteristicsDuration of study monthsPatients (completed study visits)NAC (daily dose) mgDisease characteristicsAverage age yearsMale %Current smokers %Smoking history pack-yearsICS treatment %Post-bronchodilator FEV1 % predictedJadad score
Zheng et al. [1], 2014Multicentre, prospective, randomised, double-blind, placebo-controlled, parallel groups129641200COPD diagnosis using PFT, GOLD II–IV66.381.917.836.244.048.94
Tse et al. [20], 2013Double-blind, randomised placebo-controlled121081200COPD diagnosis using PFT, GOLD I–IV70.993.323.3NA79.059.64
Schermer et al. [26], 2009Double blind, randomised, double dummy, placebo-controlled36108600COPD diagnosis using PFT, GOLD I–IV, chronic bronchitis59.472.953.627.349.069.84
Bachh et al. [27], 2007Single blind, randomised, placebo-controlled study4100600COPD diagnosis using PFT, GOLD II and III61.478.0NA44.118.051.71
Decramer et al. [3], 2005Double-blind, randomised, placebo-controlled, parallel groups36354600COPD diagnosis using PFT, GOLD II and III62.077.044.0NA70.057.04
Gerrits et al. [29], 2003Retrospective cohort investigation121219From 200 to >600ICD-9: 491, 492, 496>5559.6NANA35.9NANA
Pela et al. [24], 1999Open, randomised, controlled6167600COPD diagnosis using PFT and ATS/ERS criteria, FEV1 <70% pred66.075.724.0NA39.658.12
Hansen et al. [19], 1994Multicentre, double-blind, randomised placebo-controlled, parallel groups5.51291200Chronic bronchitis, FEV1 >50% pred51.443.192.2NANANA4
Rasmussen and Glennow [25], 1988Multicentre, double-blind, randomised placebo-controlled, parallel groups691600Chronic bronchitis58.856.9NANANANA4
McGavin et al. [22], 1985Multicentre, double-blind, randomised, placebo-controlled, parallel groups5148600Chronic bronchitis, FEV1 <50% pred, FEV1/FVC <70% predNA85.627.1NA25.430.0#4
Boman et al. [23], 1983Multicentre, double-blind, randomised, placebo-controlled, parallel groups6203400Chronic bronchitis, FEV1 >50% pred52NA81.3NANA80.0#1
Babolini et al. [21], 1980Multicentre, double-blind, randomised, placebo-controlled, parallel groups6495400Chronic bronchitis, FEV1 >40% pred>5076.666.3NANANA1
Grassi and Morandini [28], 1976Double-blind, randomised, placebo-controlled669260Chronic bronchitis6179.7NANANANA3
  • Data are presented as n, unless otherwise stated. NAC: N-acetylcysteine; ICS: inhaled corticosteroid; FEV1: forced expiratory volume in 1 s; COPD: chronic obstructive pulmonary disease; PFT: pulmonary function testing; GOLD: Global Initiative for Chronic Obstructive Lung Disease; NA: not available; ICD: International Classification of Diseases; ATS: American Thoracic Society; ERS: European Respiratory Society; FVC: forced vital capacity. #: post-bronchodilator not defined.